General MedicationsORALGeneric
STAVUDINE; LAMIVUDINE
STAVUDINE; LAMIVUDINE
Standard Dose
30MG; 150MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: None (Tentative Approval)
Summary
Approval overview STAVUDINE; LAMIVUDINE is listed in Drugs@FDA under application 022347 (NDA).
Review priority: STANDARD Marketing status: None (Tentative Approval) Active ingredient STAVUDINE; LAMIVUDINE Form and strength TABLET; ORAL - 30MG; 150MG Sponsor PHARMACARE LTD Submission history Latest submission status date: 2009-03-18 00:00:00.
Structured Monograph
Clinical summary
Approval overview STAVUDINE; LAMIVUDINE is listed in Drugs@FDA under application 022347 (NDA). Review priority: STANDARD Marketing status: None (Tentative Approval) Active ingredient STAVUDINE; LAMIVUDINE Form and strength TABLET; ORAL - 30MG; 150MG Sponsor PHARMACARE LTD Submission history Latest submission status date: 2009-03-18 00:00:00. Submission type: ORIG.
Monitoring
- • Marketing status: None (Tentative Approval)
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.